Latest Insider Transactions at Evolus, Inc. (EOLS)
This section provides a real-time view of insider transactions for Evolus, Inc. (EOLS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Evolus, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Evolus, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 07
2024
|
Robert Hayman Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,464
+10.54%
|
-
|
|
Feb 07
2024
|
Brady Stewart Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,464
+11.2%
|
-
|
|
Feb 07
2024
|
David N Gill Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,464
+12.73%
|
-
|
|
Feb 07
2024
|
Simone Blank Director |
BUY
Grant, award, or other acquisition
|
Direct |
6,464
+8.48%
|
-
|
|
Jan 30
2024
|
Karah Herdman Parschauer Director |
SELL
Open market or private sale
|
Direct |
11,931
-27.63%
|
$155,103
$13.14 P/Share
|
|
Dec 08
2023
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
31,300
-4.93%
|
$281,700
$9.73 P/Share
|
|
Dec 06
2023
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
51,348
-7.48%
|
$513,480
$10.09 P/Share
|
|
Oct 16
2023
|
Medytox Inc. |
SELL
Open market or private sale
|
Direct |
1,690,663
-33.33%
|
$11,834,641
$7.5 P/Share
|
|
Sep 06
2023
|
Sandra Beaver Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,178
-2.73%
|
$28,602
$9.7 P/Share
|
|
Aug 21
2023
|
Tomoko Yamagishi Dressler Chief Marketing Officer |
BUY
Grant, award, or other acquisition
|
Direct |
63,358
+50.0%
|
-
|
|
Aug 16
2023
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
14,778
-2.11%
|
$147,780
$10.27 P/Share
|
|
Aug 16
2023
|
Sandra Beaver Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,211
-1.86%
|
$22,110
$10.27 P/Share
|
|
Aug 16
2023
|
Rui Avelar Officer |
SELL
Open market or private sale
|
Direct |
2,211
-0.62%
|
$22,110
$10.27 P/Share
|
|
Aug 15
2023
|
Vikram Malik Director |
BUY
Open market or private purchase
|
Direct |
174,967
+38.84%
|
$1,224,769
$7.41 P/Share
|
|
Aug 14
2023
|
David Moatazedi Director |
BUY
Grant, award, or other acquisition
|
Direct |
91,803
+11.57%
|
-
|
|
Aug 14
2023
|
Sandra Beaver Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,672
+14.21%
|
-
|
|
Aug 14
2023
|
Rui Avelar Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,672
+5.24%
|
-
|
|
Aug 11
2023
|
Robert Hayman Director |
BUY
Other acquisition or disposition
|
Indirect |
366
+3.41%
|
-
|
|
Aug 11
2023
|
Robert Hayman Director |
BUY
Other acquisition or disposition
|
Direct |
218
+0.45%
|
-
|
|
Aug 11
2023
|
Simone Blank Director |
BUY
Other acquisition or disposition
|
Indirect |
115,206
+19.27%
|
-
|
|
Aug 11
2023
|
Simone Blank Director |
BUY
Other acquisition or disposition
|
Direct |
109
+0.17%
|
-
|
|
Aug 11
2023
|
Vikram Malik Director |
BUY
Other acquisition or disposition
|
Direct |
22,998
+18.61%
|
-
|
|
Mar 27
2023
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
6,110
-0.99%
|
$48,880
$8.47 P/Share
|
|
Mar 14
2023
|
Rui Avelar Officer |
SELL
Open market or private sale
|
Direct |
14,906
-4.25%
|
$119,248
$8.47 P/Share
|
|
Mar 14
2023
|
David Moatazedi Director |
SELL
Open market or private sale
|
Direct |
64,211
-9.44%
|
$513,688
$8.47 P/Share
|
|
Feb 17
2023
|
Alphaeon 1 LLC |
SELL
Open market or private sale
|
Direct |
1,850,000
-30.5%
|
$14,800,000
$8.4 P/Share
|
|
Feb 07
2023
|
Medytox Inc. |
SELL
Open market or private sale
|
Direct |
2,187,511
-30.13%
|
$17,500,088
$8.5 P/Share
|
|
Jan 27
2023
|
Peter C Farrell Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,293
+16.11%
|
-
|
|
Jan 27
2023
|
David N Gill Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,293
+17.97%
|
-
|
|
Jan 27
2023
|
Simone Blank Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,293
+11.6%
|
-
|
|
Jan 27
2023
|
Karah Herdman Parschauer Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,293
+16.11%
|
-
|
|
Jan 27
2023
|
Vikram Malik Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,293
+9.66%
|
-
|
|
Jan 27
2023
|
Robert Hayman Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,293
+14.69%
|
-
|
|
Jan 27
2023
|
Brady Stewart Director |
BUY
Grant, award, or other acquisition
|
Direct |
8,293
+15.62%
|
-
|
|
Jan 25
2023
|
David Moatazedi Director |
BUY
Grant, award, or other acquisition
|
Direct |
187,927
+21.66%
|
-
|
|
Jan 25
2023
|
Rui Avelar Officer |
BUY
Grant, award, or other acquisition
|
Direct |
97,642
+21.77%
|
-
|
|
Jan 25
2023
|
Sandra Beaver Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
62,642
+38.73%
|
-
|
|
Jan 20
2023
|
Medytox Inc. |
SELL
Open market or private sale
|
Indirect |
37,043
-0.51%
|
$407,473
$11.04 P/Share
|
|
Oct 06
2022
|
Medytox Inc. |
SELL
Open market or private sale
|
Direct |
38,304
-0.52%
|
$306,432
$8.99 P/Share
|
|
Oct 05
2022
|
Medytox Inc. |
SELL
Open market or private sale
|
Direct |
6,848
-0.09%
|
$54,784
$8.95 P/Share
|
|
Sep 15
2022
|
Medytox Inc. |
SELL
Open market or private sale
|
Direct |
24,000
-0.33%
|
$240,000
$10.34 P/Share
|
|
Sep 14
2022
|
Medytox Inc. |
SELL
Open market or private sale
|
Direct |
73,000
-0.99%
|
$730,000
$10.27 P/Share
|
|
Sep 12
2022
|
Robert Hayman Director |
BUY
Open market or private purchase
|
Indirect |
1,091
+9.84%
|
$10,910
$10.78 P/Share
|
|
Sep 09
2022
|
Robert Hayman Director |
BUY
Open market or private purchase
|
Indirect |
8,909
+50.0%
|
$89,090
$10.35 P/Share
|
|
Sep 09
2022
|
Medytox Inc. |
SELL
Open market or private sale
|
Direct |
20,700
-0.28%
|
$207,000
$10.53 P/Share
|
|
Sep 08
2022
|
Medytox Inc. |
SELL
Open market or private sale
|
Direct |
15,300
-0.21%
|
$153,000
$10.39 P/Share
|
|
Sep 07
2022
|
Robert Hayman Director |
BUY
Open market or private purchase
|
Direct |
4,967
+11.08%
|
$49,670
$10.05 P/Share
|
|
Sep 06
2022
|
Simone Blank Director |
BUY
Open market or private purchase
|
Direct |
20,000
+26.71%
|
$180,000
$9.24 P/Share
|
|
Sep 06
2022
|
Peter C Farrell Director |
BUY
Open market or private purchase
|
Indirect |
10,000
+50.0%
|
$90,000
$9.1 P/Share
|
|
Sep 05
2022
|
Sandra Beaver Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
36,443
+50.0%
|
-
|